Arca
Skip to content
Tools
Tools

Label Changes: Talzenna (talazoparib tosylate)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Talzenna label DailyMed has published, from Pfizer Laboratories Div Pfizer Inc, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 20
  • Sections changed, version 19 to 20: 11

What changed from version 19 to version 20

Dec 19, 2025 to Oct 30, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Indications and usageChanged · 79 words added, 44 removed
  2. Dosage and administrationChanged · 95 words added, 79 removed
  3. Warnings and precautionsChanged · 99 words added, 122 removed
  4. Adverse reactionsChanged · 787 words added, 162 removed
  5. Drug interactionsChanged · 7 words added, 3 removed
  6. Use in specific populationsChanged · 129 words added, 26 removed
  7. Clinical pharmacologyChanged · 5 words added, 4 removed
  8. Clinical studiesChanged · 681 words added, 141 removed
  9. How suppliedChanged · 2 words added, 2 removed
  10. Patient informationChanged · 112 words added, 109 removed
  11. Untitled sectionChanged · 1 word added, 1 removed

Indications and usage

Changed79 words added, 44 removed
1 unchanged line
1.1 BRCA-mutated (gBRCAm) HER2-negative Locally Advanced or Metastatic Breast Cancer
TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approvedauthorized companion diagnostic for TALZENNA [see Dosage and Administration (2.1)].
1.2 HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1.2 HRR Gene-Mutated Metastatic Prostate Cancer
TALZENNA is indicated in combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) [see Dosage and Administration (2.3)].
TALZENNA is indicated in combination with enzalutamide for the treatment of adult patients with:
•metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test [see Dosage and Administration (2.1) ].
• metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with HRR gene mutations, as detected by an FDA-authorized test [see Dosage and Administration (2.1)].

Dosage and administration

Changed95 words added, 79 removed
1 unchanged line
2.1 Patient Selection
Information on the FDA-approved tests for the detection of genetic mutations is available at http://www.fda.gov/companiondiagnostics.
gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer
Select patients for the treatment of advanced breast cancer with TALZENNA based on the presence of germline BRCA mutations [see Indications and Usage (1.1), Clinical Studies (14.1)].
HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer
HRR Gene-Mutated mAPMR and mAPMN/S Prostate Cancer
Select patients for the treatment of HRR gene-mutated mCRPCmAPMR or mAPMN/S prostate cancer with TALZENNA based on the presence of alterations in genes directly or indirectly involved in HRR (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C) [see Indications and Usage (1.2), Clinical Studies (14.2)].
An FDA-approved test for the detection of HRR gene mutations for use with TALZENNA is not currently available.
Information on the FDA-authorized tests for the detection of genetic mutations is available at http://www.fda.gov/companiondiagnostics.
2.2 Recommended Dosage for gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer
The recommended dosage of TALZENNA is 1 mg taken orally once daily, until disease progression or unacceptable toxicity.
2.3 Recommended Dosage for HRR Gene-mutated mCRPC
2.3 Recommended Dosage for HRR Gene-Mutated mAPMR and mAPMN/S Prostate Cancer
The recommended dosage of TALZENNA is 0.5 mg taken orally once daily with enzalutamide until disease progression or unacceptable toxicity.
Refer to the enzalutamide prescribing information for recommended enzalutamide dosing information.
Patients receiving TALZENNA and enzalutamide should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.
2.4 Administration
Take TALZENNA with or without food.
Take TALZENNA with or without food [see Clinical Pharmacology (12.3)].
Swallow TALZENNA capsules whole. Do not open or dissolve.
1 unchanged line
2.5 Dosage Modifications for Adverse Reactions
To manage adverse reactions, consider interruption of treatment with or without dose reduction based on severity and clinical presentation. Recommended dose reductions are indicated in Table 1 and Table 2. Treatment with TALZENNA should be permanently discontinued if more than 3 dose reductions are required.
gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer
5 unchanged lines
Third dose reduction | 0.25 mg once daily
HRR Gene-mutated mCRPC
HRR Gene-Mutated mAPMR and mAPMN/S Prostate Cancer
Table 2. Dose Reduction Levels for Adverse Reactions—mCRPCmAPMR and mAPMN/S Prostate Cancer
Dose Reductions | Dose Level
4 unchanged lines
Refer to the enzalutamide prescribing information for dose modifications for adverse reactions associated with enzalutamide.
gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer and; HRR Gene-mutatedMutated mCRPCmAPMR and mAPMN/S Prostate Cancer
Monitor complete blood counts monthly and as clinically indicated [see Warnings and Precautions (5.2)].
3 unchanged lines
Platelet count <50,000/μL | ≥75,000/μL
Neutrophil count <1,000/μL | ≥15001,500/µL
Non-hematologic Grade 3 or Grade 4 | ≤Grade 1 | Consider resuming TALZENNA at a reduced dose or discontinue
3 unchanged lines
The recommended dosage of TALZENNA for patients with severe renal impairment (CLcr 15 - 29 mL/min) is 0.5 mg taken orally once daily [see Use in Specific Populations (8.7)].
HRR Gene-mutated mCRPC
HRR Gene-Mutated mAPMR and mAPMN/S Prostate Cancer
The recommended dosage of TALZENNA for patients with moderate renal impairment (CLcr 30 - 59 mL/min) is 0.35 mg taken orally once daily with enzalutamide [see Use in Specific Populations (8.7)].
2 unchanged lines
gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer
Avoid coadministration of TALZENNA with the following P-glycoprotein (P-gp) inhibitors: itraconazole, amiodarone, carvedilol, clarithromycin, itraconazole, and verapamil. If coadministration of TALZENNA with these P-gp inhibitors cannot be avoided, reduce the dose of TALZENNA to 0.75 mg taken orally once daily. When the P-gp inhibitor is discontinued, increase the dose of TALZENNA (after 3 – 5 half-lives of the P-gp inhibitor) to the dose of TALZENNA that was used before starting the P-gp inhibitor [see Drug Interactions (7.1)].
Monitor for increased adverse reactions and modify the dosage as recommended for adverse reactions when TALZENNA is coadministered with other P-gp inhibitors [see Dosage and Administration (2.5)].

Warnings and precautions

Changed99 words added, 122 removed
2 unchanged lines
Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), including cases with a fatal outcome, has been reported in patients who received TALZENNA.
Overall, MDS/AML has been reported in 0.4% (3 out of 788) of solid tumor patients treated with TALZENNA as a single agent in clinical studies. In TALAPRO-2, MDS/AML occurred in 2 out of 511 (0.4%) patients treated with TALZENNA and enzalutamide and in 0 out of 517 (0%) patients treated with placebo and enzalutamide [see Adverse Reactions (6.1)]. The durations of TALZENNA treatment in these 5 patients prior to developing MDS/AML were 0.3, 1, 2, 3, and 5 years. Most of these patients had received previous chemotherapy with platinum agents and/or other DNA damaging agents including radiotherapy.
In clinical studies, among 1,096 patients treated with TALZENNA as a single agent or as part of a combination regimen with enzalutamide, the cumulative incidence of MDS/AML was approximately 1% [see Adverse Reactions (6.1)] including 0.6% with fatal outcomes. The incidence of MDS/AML among patients treated with active control or with placebo in combination with enzalutamide was 0.2%. The median duration of therapy with TALZENNA in patients who developed MDS/AML was approximately 2.8 years (range: 1 to 5.8 years).
Do not start TALZENNA until patients have adequately recovered from hematological toxicity caused by previous chemotherapy. Monitor blood counts monthly during treatment with TALZENNA. For prolonged hematological toxicities, interrupt TALZENNA and monitor blood counts weekly until recovery. If counts do not recover within 4 weeks, refer the patient to a hematologist for further investigations including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue TALZENNA.
5.2 Myelosuppression
Myelosuppression consisting of anemia, leukopenia/neutropenia, and/or thrombocytopenia, havehas been reported in patients treated with TALZENNA [see Adverse Reactions (6.1)].
Grade ≥3 anemia, neutropenia, and thrombocytopenia were reported, respectively, in 39%, 21%, and 15% of patients receiving TALZENNA as a single agent. Discontinuation due to anemia, neutropenia, and thrombocytopenia occurred, respectively, in 0.7%, 0.3%, and 0.3% of patients.
In TALAPRO-2, Grade ≥3 anemia, neutropenia, and thrombocytopenia were reported, respectively, in 4849%, 19%, and 9% of patients receiving TALZENNA andin combination with enzalutamide. Forty-twoone percent of patients (216/511) required a red blood cell transfusion, including 25% (127/511) who required more than one transfusion. Discontinuation due to anemia, neutropenia, and thrombocytopenia occurred, respectively, in 87%, 34%, and 0.41% of patients.
Withhold TALZENNA until patients have adequately recovered from hematological toxicity caused by previous therapy. Monitor blood counts monthly during treatment with TALZENNA. If hematological toxicities do not resolve within 28 days, discontinue TALZENNA and refer the patient to a hematologist for further investigations including bone marrow analysis and blood sample for cytogenetics [see Dosage and Administration (2.5)].
5.3 Embryo-Fetal Toxicity
Based on its mechanism of action and findings from animal data, TALZENNA can cause fetal harm when administered to a pregnant woman. In an animal reproduction study, administration of talazoparib to pregnant rats during the period of organogenesis caused fetal malformations and structural skeletal variations, and embryo-fetal death at exposures that were 0.24 times the area under the concentration-time curve (AUC) in patients receiving the recommended human dose of 1 mg daily. AppriseAdvise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the last dose of TALZENNA [see Use in Specific Populations (8.1, 8.3), Clinical Pharmacology (12.1)].
Based on findings from genetic toxicity and animal reproduction studies, advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 4 months following the last dose of TALZENNA [see Use in Specific Populations (8.1, 8.3), Nonclinical Toxicology (13.1)].

Adverse reactions

Changed787 words added, 162 removed
5 unchanged lines
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described in the WARNINGS AND PRECAUTIONS section reflect exposure to single agent TALZENNA in solid tumor clinical studies, including 286 patients enrolled in EMBRACA trial and to TALZENNA 0.5 mg daily with enzalutamide in 511 patients enrolled in the TALAPRO-2 trial that included 197 patients with HRR gene-mutated mCRPC.
The data described in the WARNINGS AND PRECAUTIONS section reflect exposure to single agent TALZENNA among the 286 patients enrolled in the EMBRACA trial, TALZENNA 0.5 mg daily with enzalutamide in 511 patients enrolled in the TALAPRO-2 trial that included 197 patients with HRR gene-mutated mAPMR prostate cancer, and TALZENNA 0.5 mg daily with enzalutamide in 299 patients with HRR gene-mutated mAPMN/S prostate cancer enrolled in the TALAPRO-3 trial. Among the 810 patients with prostate cancer, 68% were exposed for greater than 1 year, 52% were exposed for greater than 2 years, and 35% were exposed for greater than 3 years. In this safety population, the most common (≥20%) adverse reactions including laboratory abnormalities were decreased hemoglobin (86%), decreased neutrophils (68%), decreased lymphocytes (62%), decreased platelets (54%), fatigue (48%), decreased albumin (26%), decreased calcium (26%), back pain (24%), decreased appetite (22%), and nausea (21%).
gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer
3 unchanged lines
Permanent discontinuation due to adverse reactions occurred in 5% of TALZENNA patients. Dosing interruptions due to an adverse reaction of any grade occurred in 65% of patients receiving TALZENNA; dose reductions due to any cause occurred in 53% of TALZENNA patients.
The most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased hemoglobin, decreased, neutrophils, decreased, lymphocytes, decreased, platelets decreased, fatigue, increased glucose, increased, aspartate aminotransferase increased(AST), increased alkaline phosphatase increased(ALP), increased alanine aminotransferase increased(ALT), calcium decreased calcium, nausea, headache, vomiting, alopecia, diarrhea, and decreased appetite.
Table 5 and Table 6 summarize the most common adverse reactions and laboratory abnormalities, respectively, in patients treated with TALZENNA or chemotherapy in the EMBRACA study.
25 unchanged lines
Glucose increased | 54 | 2 | 0 | 51 | 2 | 0
Aspartate aminotransferase Increased | 37 | 2 | 0 | 48 | 3 | 0
AST increased | 37 | 2 | 0 | 48 | 3 | 0
Alkaline phosphataseALP increased | 36 | 2 | 0 | 34 | 2 | 0
Alanine aminotransferaseALT increased | 33 | 1 | 0 | 37 | 2 | 0
Calcium decreased | 28 | 1 | 0 | 16 | 0 | 0
HRR Gene-mutated mCRPC
HRR Gene-Mutated Prostate Cancer
TALAPRO-2 for mAPMR Prostate Cancer
The safety of TALZENNA in combination with enzalutamide was evaluated in patients with HRR gene-mutated mCRPCmAPMR prostate cancer enrolled in TALAPRO-2 [see Clinical Studies (14.2)]. Patients were randomized to receive either TALZENNA 0.5 mg with enzalutamide 160 mg once daily (n=197), or placebo with enzalutamide 160 mg once daily (n=199) until disease progression or unacceptable toxicity. Among patients receiving TALZENNA, 86% were exposed for 6 months or longer, 60% were exposed for greater than one year, and 18% were exposed for greater than two years.
Serious adverse reactions of TALZENNA with enzalutamide occurred in 30% of patients. Serious adverse reactions reported in >2% of patients included anemia (9%) and fracture (3%). Fatal adverse reactions occurred in 1.5% of patients, including pneumonia, COVID infection, and sepsis (1 patient each).
Permanent discontinuation of TALZENNA due to adverse reactions occurred in 10% of patients treated in the TALZENNA with enzalutamide arm. The most common adverse reactions which resulted in permanent discontinuation of TALZENNA were anemia (4%), fatigue, bone fracture, ischemic heart disease, and spinal cord compression (1% each).
Dosage interruption of TALZENNA due to adverse reactions occurred in 58% of patients treated in the TALZENNA with enzalutamide arm. The most common adverse reactions whichthat resulted in dose interruption of TALZENNA were anemia (42%), neutropenia (15%), and platelet count decreasedthrombocytopenia (9%), and fatigue (5%).
Dose reduction of TALZENNA due to adverse reactions occurred in 52% of patients treated in the TALZENNA with enzalutamide arm. The most common adverse reactions which resulted in dose reduction of TALZENNA were anemia (43%), neutrophil count decreasedneutropenia (15%), platelet count decreasedthrombocytopenia (6%), and fatigue (4%).
The most common adverse reactions (≥10%), including laboratory abnormalities, in patients who received TALZENNA with enzalutamide were hemoglobin decreased, neutrophils decreased, lymphocytes decreased, fatigue, platelets decreased, calcium decreased, nausea, decreased appetite, sodium decreased, phosphate decreased, fractures, magnesium decreased, dizziness, bilirubin increased, potassium decreased, and dysgeusia.
Table 7 and Table 8 summarize the most common adverse reactions and laboratory abnormalities, respectively, in the TALAPRO-2 study.
3 unchanged lines
Grades 1-4 % | Grade 3 % | Grade 4 % | Grades 1-4 % | Grade 3 % | Grade 4 %
General Disorders and Administration Site Conditions
Fatigue | 49 | 4 | 0 | 40 | 1 | 0
Gastrointestinal Disorders
Nausea | 21 | 2 | 0 | 17 | 1 | 0.5
Metabolism and Nutrition Disorders
Decreased appetite | 20 | 1 | 0 | 14 | 1 | 1
Injury, Poisoning and Procedural Complications
Fractures | 14 | 3 | 0 | 10 | 1.5 | 0
Nervous System Disorder
Dizziness | 13 | 1.5 | 0 | 9 | 1.5 | 0
Dysgeusia | 10 | 0 | 0 | 4.5 | 0 | 0
Clinically relevant adverse reactions in <10% of patients who received TALZENNA with enzalutamide included abdominal pain (9%), vomiting (9%), alopecia (7%), dyspepsia (4%), venous thromboembolism (3%), and stomatitis (2%).
Table 8. Select Laboratory Abnormalities (≥10%) That Worsened from Baseline in Patients Who Received TALZENNA (with a Difference Between Arms of ≥2%) in TALAPRO-2
Abbreviation: N=number of patients.
11 unchanged lines
Potassium decreased | 11 | 0 | 1 | 7 | 1 | 0.5
TALAPRO-3 for mAPMN/S Prostate Cancer
The safety of TALZENNA in combination with enzalutamide was evaluated in patients with HRR gene-mutated mAPMN/S prostate cancer enrolled in TALAPRO-3 [see Clinical Studies (14.2)]. Patients were randomized to receive either TALZENNA 0.5 mg with enzalutamide 160 mg once daily (n=299), or placebo with enzalutamide 160 mg once daily (n=295) until disease progression or unacceptable toxicity.
Serious adverse reactions of TALZENNA in combination with enzalutamide occurred in 42% of patients. Serious adverse reactions reported in >2% of patients included anemia (14%), thrombocytopenia (3%), and urinary tract infection (2%). Fatal adverse reactions occurred in 3% of patients, including cardiac arrest, death, general physical health deterioration, idiopathic pulmonary fibrosis, pancytopenia, and second primary malignancy (1 patient each).
Permanent discontinuation of TALZENNA due to adverse reactions occurred in 19% of patients. The most common adverse reactions that resulted in permanent discontinuation of TALZENNA were neutropenia (6%), anemia (5%), thrombocytopenia and fatigue (2% each), MDS/AML, dizziness, leukopenia, dyspnea, nausea, second primary malignancy, and spinal cord compression (1% each).
Dosage interruption of TALZENNA due to adverse reactions occurred in 69% of patients. The most common adverse reactions that resulted in dosage interruption of TALZENNA were anemia (42%), neutropenia (17%), thrombocytopenia (12%), fatigue (11%), and COVID-19 (5%).
Dose reduction of TALZENNA due to adverse reactions occurred in 60% of patients. The most common adverse reactions that resulted in dose reduction of TALZENNA were anemia (45%), neutropenia (15%), thrombocytopenia and fatigue (6% each).
Table 9 and Table 10 summarize the most common adverse reactions and laboratory abnormalities, respectively, in the TALAPRO-3 study.
Table 9. Adverse Reactions (≥10%) in Patients Receiving TALZENNA (with a Difference Between Arms of ≥2%) in TALAPRO-3
| TALZENNA with Enzalutamide N=299 | Placebo with Enzalutamide N=295
Grades 1-4 % | Grade 3 % | Grade 4 % | Grades 1-4 % | Grade 3 % | Grade 4 %
General Disorders and Administration Site Conditions
Fatigue | 46 | 9 | 0 | 28 | 1 | 0
Metabolism and Nutrition Disorders
Decreased appetite | 20 | 2 | 0 | 10 | 1 | 0
Gastrointestinal Disorders
Constipation | 18 | 0 | 0 | 12 | 0 | 0
Nausea | 17 | 0 | 0 | 8 | 0 | 0
Diarrhea | 14 | 2 | 0 | 11 | 1 | 0
Abdominal pain | 11 | 1 | 0 | 6 | 0 | 0
Nervous System Disorders
Dizziness | 13 | 0 | 0 | 11 | 1 | 0
Dysgeusia | 11 | 0 | 0 | 8 | 0 | 0
Infections and Infestations
Urinary tract infection | 12 | 2 | 0 | 7 | 1 | 0
Psychiatric Disorders
Insomnia | 11 | 1 | 0 | 7 | 0 | 0
Investigations
Weight decreased | 10 | 1 | 0 | 5 | 0 | 0
Clinically relevant adverse reactions in <10% of patients who received TALZENNA in combination with enzalutamide included headache (6%), vomiting (5%), alopecia (4%), dyspepsia (4%), second primary malignancies (3%), venous thromboembolism (2%), and stomatitis (2%).
Table 10. Select Laboratory Abnormalities (≥10%) That Worsened from Baseline in Patients Who Received TALZENNA (with a Difference Between Arms of ≥2%) in TALAPRO-3
Laboratory Abnormality | TALZENNA with Enzalutamide | Placebo with Enzalutamide
Grades 1-4 % | Grade 3 % | Grade 4 % | Grade 1-4 % | Grade 3 % | Grade 4 %
Hematology
Hemoglobin decreased | 88 | 49 | 0 | 46 | 3.4 | 0
Neutrophils decreased | 71 | 18 | 4 | 24 | 2.4 | 0.3
Lymphocytes decreased | 60 | 11 | 3.3 | 39 | 6 | 0
Platelets decreased | 57 | 7 | 3 | 20 | 0.3 | 0.3
Chemistry
Calcium decreased | 22 | 0.3 | 0.3 | 17 | 1 | 0.7
Blood bilirubin increased | 18 | 1.3 | 0 | 14 | 0.3 | 0
Phosphate decreased | 13 | 1.7 | 0 | 9 | 0.7 | 0

Drug interactions

Changed7 words added, 3 removed
1 unchanged line
7.1 Effect of Other Drugs on TALZENNA
Effect of P-gp Inhibitors Breast Cancer Avoid coadministration of TALZENNA with the following P-gp inhibitors: itraconazole, amiodarone, carvedilol, clarithromycin, itraconazole, and verapamil. If coadministration of TALZENNA with these P-gp inhibitors cannot be avoided, reduce the dose of TALZENNA [see Dosage and Administration (2.7)]. When the P-gp inhibitor is discontinued, increase the dose of TALZENNA [see Dosage and Administration (2.7)].
Coadministration of TALZENNA with these P-gp inhibitors increased talazoparib concentrations [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions.
Monitor for increased adverse reactions and modify the dosage as recommended for adverse reactions when TALZENNA is coadministered with other P-gp inhibitors [see Dosage and Administration (2.5)].
HRR Gene-mutatedMutated mCRPCmAPMR and mAPMN/S Prostate Cancer The effect of coadministration of P-gp inhibitors on talazoparib exposure when TALZENNA is taken with enzalutamide has not been studied. Monitor patients for increased adverse reactions and modify the dosage as recommended for adverse reactions when TALZENNA is coadministered with a P-gp inhibitor [see Dosage and Administration (2.5)].
Effect of Breast Cancer Resistance Protein (BCRP) Inhibitors
2 unchanged lines

Use in specific populations

Changed129 words added, 26 removed
15 unchanged lines
8.5 Geriatric Use
In clinical trials of TALZENNA enrolling 494 patients with advanced solid tumors who received TALZENNA 1 mg daily as a single agent, 85 (17%) patients were ≥65 years of age, and this included 19 (4%) patients who were ≥75 years old. There were 5 patients ≥85 years old. In the TALAPRO-2 trial, of 197 patients who received TALZENNA, 77% were ≥65 years of age, while 30% were ≥75 years of age. No overall differences in safety or effectiveness of TALZENNA were observed between these patients ≥65 years of age and younger patients.
In clinical trials of TALZENNA enrolling 810 patients who received TALZENNA in combination with enzalutamide, 624 (77%) patients were ≥65 years of age, including 262 (32%) patients who were ≥75 years old. Grade 3 to 5 adverse reactions (91% vs 75%), permanent discontinuations (31% vs 14%), dosage interruptions (75% vs 63%), and dose reductions (65% vs 53%) occurred more frequently in patients ≥75 years of age than in patients <75 years of age. The differences in Grade 3 to 5 adverse reactions between patients ≥75 years of age and patients <75 years of age were primarily driven by an increased incidence of myelosuppression. No overall differences in effectiveness of TALZENNA were observed between patients ≥75 years of age and patients <75 years of age.
8.6 Hepatic Impairment
1 unchanged line
8.7 Renal Impairment
Reduce the recommended dosage of TALZENNA in patients with moderate (CLcr 30 – 59 mL/min) and severe (CLcr 15 – 29 mL/min) renal impairment [see Dosage and Administration (2.76) ]. Monitor patients with severe renal impairment for increased adverse reactions and modify the dosage as recommended for adverse reactions [see Dosage and Administration (2.5)].
No dose adjustment is recommended for patients with mild renal impairment (CLcr 60 – 89 mL/min). TALZENNA has not been studied in patients requiring hemodialysis.

Clinical pharmacology

Changed5 words added, 4 removed
7 unchanged lines
After administration of TALZENNA 1 mg orally once daily as a single agent (the recommended dosage for breast cancer), the mean [% coefficient of variation (CV%)] AUC and maximum observed plasma concentration (Cmax) of talazoparib at steady-state was 208 (37%) ng.hr/mL and 16.4 (32%) ng/mL, respectively. The mean (CV%) steady-state Ctrough was 3.53 (61%) ng/mL.
After administration of TALZENNA 0.5 mg orally once daily (the recommended dosage for prostate cancer) with enzalutamide, the mean (CV%) steady-state Ctrough ranged from 3.29 to 3.6899 ng/mL (4543% to 4849%).
The pharmacokinetics (PK) of talazoparib is linear from 0.025 mg to 2 mg (2 times the recommended dose for breast cancer). The median accumulation ratio of talazoparib following 1 mg orally once daily is 2.3 to 5.2. Talazoparib plasma concentrations reached steady-state within 2 to 3 weeks when administered as a single agent and within 9 weeks when coadministered with enzalutamide.
Absorption The median time to Cmax (Tmax) was generally between 1 to 2 hours after dosing.
Food Effect Following a single TALZENNA 0.5 mg dose with high-fat, high-calorie food (approximately 800 to 10001,000 calories with 150, 250, and 500 to 600 calories from protein, carbohydrate, and fat, respectively), the mean Cmax was decreased by 46%, the median Tmax was delayed from 1 to 4 hours, and AUC was not affected.
Distribution The mean apparent volume of distribution of talazoparib is 420 L. In vitro, protein binding of talazoparib is 74% and is independent of talazoparib concentration.
3 unchanged lines
Specific Populations Age (18 to 88 years), sex, race (361 White, 41 Asian, 16 Black, 9 Others, and 63 Not Reported), body weight (36 to 162 kg), and mild to severe hepatic impairment had no clinically significant effect on the PK of talazoparib.
Patients with Renal Impairment Mild (eGFR 60 – 89 mL/min/1.73 m2) renal impairment had no clinically significant effect on talazoparib pharmacokinetics. Talazoparib steady-state total exposure (AUC) increased by 43% in subjects with moderate (eGFR 30 – 59 mL/min/1.73 m2) renal impairment and 163% in patients with severe (eGFR 15 – 29 mL/min/1.73 m2) renal impairment relative to subjects with normal renal function (eGFR ≥ 90 mL/min/1.73 m2). Talazoparib steady-state peak concentration (Cmax) increased by 32% in subjects with moderate renal impairment and 89% in subjects with severe renal impairment, relative to subjects with normal renal function. Similar increases in AUC were observed with talazoparib when given with enzalutamide for patients with moderate and severe renal impairment. The PK of talazoparib has not been studied in patients requiring hemodialysis. There was no evidence of a relationship between the protein binding of talazoparib and renal function.
Drug Interaction Studies Clinical Studies Effect of P-gp Inhibitors: Coadministration of a P-gp inhibitor (itraconazole) with a single 0.5 mg dose of TALZENNA increased talazoparib AUC and Cmax by approximately 56% and 40%, respectively. Coadministration with the following other P-gp inhibitors: amiodarone, carvedilol, clarithromycin, itraconazole, and verapamil increased talazoparib exposure by 45%.
9 unchanged lines

Clinical studies

Changed681 words added, 141 removed
1 unchanged line
14.1 Deleterious or Suspected Deleterious Germline BRCA-mutated HER2-negative Locally Advanced or Metastatic Breast Cancer
EMBRACA (NCT01945775) was an open-label study in which patients (N=431) with gBRCAm HER2-negative locally advanced or metastatic breast cancer were randomized 2:1 to receive TALZENNA 1 mg or healthcare provider's choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine) until disease progression or unacceptable toxicity. Randomization was stratified by prior lines of chemotherapy for metastatic disease (0 versusvs 1, 2, or 3), by triple-negative disease status [triple-negative breast cancer (TNBC) versusvs non-TNBC], and history of central nervous system (CNS) metastasis (yes versusvs no).
Patients received no more than 3 prior cytotoxic chemotherapy regimens for their metastatic or locally advanced disease. Patients were required to have received treatment with an anthracycline and/or a taxane (unless contraindicated) in the neoadjuvant, adjuvant, and/or metastatic treatment setting. First-line treatment for advanced or metastatic disease with no prior adjuvant chemotherapy was allowed if the investigator determined that 1 of the 4 chemotherapy choices in the control arm would be an appropriate treatment option for the patient. Patients with prior platinum therapy for advanced disease were required to have no evidence of disease progression during platinum therapy. No prior treatment with a PARP inhibitor was permitted. Of the 431 patients randomized in the EMBRACA study, 408 (95%) were centrally confirmed to have a deleterious or suspected deleterious gBRCAm using a clinical trial assay; out of which 354 (82%) were confirmed using the BRACAnalysis CDx®. BRCA mutation status [breast cancer susceptibility gene 1 (BRCA1)-positive or breast cancer susceptibility gene 2 (BRCA2)-positive] was similar across both treatment arms.
The median age of patients treated with TALZENNA was 46 years (range: 28 to 84) and 51 years (range: 24 to 89) among patients treated with chemotherapy. Among all randomized patients, 1% versusvs 2% were males, 67% versusvs 75% were White; 11% versusvs 11% were Asian, and 4% versusvs 1% were Black or African American in the TALZENNA and chemotherapy arms, respectively. Almost all patients (98%) in both arms had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Approximately 56% of patients had estrogen receptor-positive and/or progesterone receptor-positive disease; 44% of patients had triple-negative disease, and the proportions were balanced across both treatment arms. Fifteen percent (15%) of patients in the TALZENNA arm and 14% of patients in the chemotherapy arm had a history of CNS metastases. Ninety-one percent (91%) of patients in the TALZENNA arm had received prior taxane therapy, and 85% had received prior anthracycline therapy in any setting. Sixteen percent (16%) of patients in the TALZENNA arm and 21% of patients in the chemotherapy arm had received prior platinum treatment in any setting. The median number of prior cytotoxic regimens for patients with advanced breast cancer was one; 38% received no prior cytotoxic regimens for advanced or metastatic disease, 37% received one, 20% received two, and 5% received three or more prior cytotoxic regimens.
The major efficacy outcome measure was progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by blinded independent central review (BICR). A statistically significant improvement in PFS was demonstrated for TALZENNA compared to chemotherapy. A sensitivity analysis of investigator-assessed PFS was consistent with the BICR-assessed PFS results. Consistent PFS results were observed across patient subgroups defined by study stratification factors (prior lines of chemotherapy, TNBC status, and history of CNS metastases). Efficacy data from the EMBRACA study are summarized in Table 911, and the Kaplan-Meier curves for PFS are shown in Figure 1 and final overall survival (OS) in Figure 2.
Table 911. Efficacy Results – EMBRACA Study
Abbreviations: BICR=blinded independent central review; CI=confidence interval; DOR=duration of response; ITT=intent-to-treat; N=number of patients; ORR=objective response rate; OS=overall survival; PFS=progression-free survival.
17 unchanged lines
Abbreviations: ITT=intent-to-treat; OS=overall survival.
14.2 HRR Gene-mutated mCRPC
14.2 HRR Gene-Mutated Prostate Cancer
mAPMR Prostate Cancer
TALAPRO-2
The efficacy of TALZENNA with enzalutamide was evaluated in TALAPRO-2 (NCT03395197), a randomized, double-blind, placebo-controlled, multi-cohort trial in which 399 patients with HRR gene-mutated (HRRm) mCRPCmAPMR prostate cancer were randomized 1:1 to receive enzalutamide 160 mg daily plus either TALZENNA 0.5 mg or placebo daily until unacceptable toxicity or disease progression. Mutation status of HRR genes was determined prospectively using solid tumor tissue or circulating tumor DNA (ctDNA)-based next generation sequencing assaystests. Patients were required to have a mutation in at least one of 12 genes involved directly or indirectly in the HRR pathway (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C). All patients received a GnRH analog or had had a prior bilateral orchiectomy and needed to have progressed on prior androgen deprivation therapy. Prior treatment with a CYP17 inhibitor or docetaxel for metastatic castration-sensitivemAPMN/S prostate cancer (mCSPC) was permitted. Randomization was stratified by previous treatment with a CYP17 inhibitor or docetaxel (yes/no).
The median age was 70 years (range: 41 to 90); 100% were male; 68% were White, 21% Asian, 2.8% Black, 0.8% Other, 7% unknown/not reported; 12% were Hispanic/Latino; and baseline ECOG performance status was 0 (62%) or 1 (38%). Thirty-nine percent of patients had bone-only disease; 15% had visceral disease. In the mCSPCmAPMN/S prostate cancer setting, 29% percent of patients had received docetaxel and 9% had received a prior CYP17 inhibitor. The most commonly mutated HRR genes (>5%), including co-occurring mutations, were: BRCA2 (34%), ATM (22%), CDK12 (19%), CHEK2 (18%), and BRCA1 (6%).
The major efficacy outcome measure was radiographic progression-free survival (rPFS) evaluated according to RECIST, version 1.1 and Prostate Cancer Working Group (PCWG3) (bone) criteria, assessed by blinded independent central review (BICR). An additional efficacy outcome measure was overall survival (OS).
A statisticallyStatistically significant improvementimprovements in rPFS and OS were demonstrated in patients randomized to TALZENNA with enzalutamide compared with placebo with enzalutamide. Efficacy results are presented in Table 1012, and Figures 3 and 4.
Table 1012. Efficacy Results – TALAPRO-2 (HRRHRRm Gene-mutatedmAPMR mCRPCProstate Cancer)
Abbreviations: BICR=blinded independent central review; CI=confidence interval; CSPC=castration-sensitive prostate cancer; HRR=homologous recombination repair; mCRPC=metastatic castration-resistant prostate cancer; N=number of patients; NR=not reached.
Abbreviations: CI=confidence interval; NR=not reached.
| TALZENNA with Enzalutamide N=200 | Placebo with Enzalutamide N=199
Radiographic Progression-freeFree Survival (rPFS) by BICR
Number of events, n (%) | 66 (33) | 104 (52)
2 unchanged lines
p-value | p<0.0001
Overall Survival (OS)
Deaths, n (%) | 93 (47) | 126 (63)
2 unchanged lines
p-value | p=0.0005
Figure 3. Kaplan-Meier Curves of rPFS - TALAPRO-2 (HRRHRRm Gene-mutatedmAPMR mCRPCProstate Cancer)
Abbreviations: HRR=homologous recombination repair; mCRPC=metastatic castration-resistant prostate cancer; rPFS=radiographic progression-free survival.
Figure 4. Kaplan-Meier Curves of OS – TALAPRO-2 (HRRHRRm Gene-mutatedmAPMR mCRPCProstate Cancer)
Abbreviations: HRR=homologous recombination repair; mCRPC=metastatic castration-resistant prostate cancer; OS=overall survival.
Exploratory subgroup analyses of rPFS and OS for patients with BRCA-mutated (BRCAm) and non-BRCAm HRRm are presented in Table 1113.
Table 1113. Exploratory rPFS and OS Subgroup Analyses by BRCAm Status for TALAPRO-2 (HRRHRRm Gene-mutatedmAPMR mCRPCProstate Cancer)
Abbreviations: BRCAm=breast cancer susceptibility gene-mutated; CI=confidence interval; CSPC=castration-sensitive prostate cancer; HRRm=homologous recombination repair gene-mutated; NR=not reached; rPFS=radiographic progression-free survival.
Abbreviations: CI=confidence interval; NR=not reached.
| BRCAm | Non-BRCAm HRRm
TALZENNA with Enzalutamide N=71 | Placebo with Enzalutamide N=84 | TALZENNA with Enzalutamide N=129 | Placebo with Enzalutamide N=115
rPFS
Radiographic Progression-Free Survival
Number of events, n (%) | 15 (21) | 54 (64) | 51 (40) | 50 (43)
1 unchanged line
Hazard ratio (95% CI) | 0.20 (0.11, 0.36) | 0.74 (0.50, 1.09)
Overall Survival (OS)
Deaths, n (%) | 30 (42) | 56 (67) | 63 (49) | 70 (61)
1 unchanged line
Hazard ratio (95% CI) | 0.48 (0.31, 0.75) | 0.71 (0.51, 1.00)
mAPMN/S Prostate Cancer
TALAPRO-3
The efficacy of TALZENNA in combination with enzalutamide was evaluated in TALAPRO-3 (NCT04821622), a randomized, double-blind, placebo-controlled, trial in which 599 patients with HRRm mAPMN/S prostate cancer were randomized 1:1 to receive enzalutamide 160 mg daily plus either TALZENNA 0.5 mg or placebo daily until unacceptable toxicity or disease progression. Mutation status of HRR genes was determined prospectively using solid tumor tissue or ctDNA-based next generation sequencing tests. Patients were required to have a mutation in at least one of 12 genes involved directly or indirectly in the HRR pathway (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C). All patients received a GnRH analog, or had a prior bilateral orchiectomy. Patients must have initiated androgen deprivation therapy or undergone a bilateral orchiectomy in the mAPMN/S prostate cancer setting up to 3 months prior to randomization with or without an androgen receptor pathway inhibitor (ARPI) but were not allowed to have received prior docetaxel. Randomization was stratified by de novo mAPMN/S vs relapsed mAPMN/S prostate cancer, high vs low volume disease, and BRCA vs non-BRCA mutational status.
The median age was 70 years (range: 44 to 89); 100% were male; 57% were White, 39% Asian, 2% Black, 1% Other, 2% unknown/not reported; 10% were Hispanic/Latino, 87% were Not Hispanic or Latino, 3% unknown/not reported; and baseline ECOG performance status was 0 (68%) or 1 (32%). Thirteen percent of patients had received a prior ARPI in the mAPMN/S setting. There were 398 (66%) and 438 (73%) patients with high volume disease and de novo mAPMN/S prostate cancer, respectively, and 307 (51%) with both de novo and high-volume disease. The most commonly mutated HRR genes (>5%), including co-occurring mutations, were: BRCA2 (30%), ATM (28%), CDK12 (19%), CHEK2 (15%) and ATR (7%).
The major efficacy outcome measure was rPFS evaluated according to RECIST, version 1.1 and PCWG3 (bone) criteria, assessed by investigator. An additional efficacy outcome measure was OS.
A statistically significant improvement in rPFS was demonstrated in patients randomized to TALZENNA with enzalutamide compared with those randomized to placebo with enzalutamide. At the time of the rPFS analysis, OS data were immature with 28% deaths in the overall population. Efficacy results are presented in Table 14 and Figure 5.
Table 14. Efficacy Results – TALAPRO-3 (HRRm mAPMN/S Prostate Cancer)
Abbreviations: CI=confidence interval; NR=not reached.
| TALZENNA with Enzalutamide N=300 | Placebo with Enzalutamide N=299
Radiographic Progression-Free Survival by Investigator
Number of events, n (%) | 67 (22) | 126 (42)
Median months (95% CI) | NR (NR, NR) | 45.8 (37.7, NR)
Hazard ratio (95% CI) | 0.48 (0.36, 0.65)
p-value | p<0.0001
Figure 5. Kaplan-Meier Curves of rPFS - TALAPRO-3 (HRRm mAPMN/S Prostate Cancer)
Exploratory subgroup analyses of rPFS for patients with BRCAm and non-BRCAm HRRm are presented in Table 15.
Table 15. rPFS Subgroup Analyses by BRCAm Status for TALAPRO-3 (HRRm mAPMN/S Prostate Cancer)
| BRCAm | Non-BRCAm HRRm
TALZENNA with Enzalutamide N=104 | Placebo with Enzalutamide N=103 | TALZENNA with Enzalutamide N=196 | Placebo with Enzalutamide N=196
Abbreviations: CI=confidence interval; IRT=interactive response technology; NR=not reached.
Radiographic Progression-Free Survival by Investigator
Number of events, n (%) | 22 (21) | 49 (48) | 45 (23) | 77 (39)
Median months (95% CI) | NR (NR, NR) | 35.1 (18.6, NR) | NR (NR, NR) | NR (40.5, NR)
Hazard ratio (95% CI) | 0.37 (0.22, 0.61) | 0.57 (0.39, 0.82)

How supplied

Changed2 words added, 2 removed
16 HOW SUPPLIED/STORAGE AND HANDLING
TALZENNA is supplied in strengths and package configurations as described in Table 1216:
Table 1216. TALZENNA Capsules
Package Configuration | Capsule Strength (mg) | NDC | Print
8 unchanged lines

Patient information

Changed112 words added, 109 removed
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 610/20252026
PATIENT INFORMATION TALZENNA® (Tal-ZEN-ah) (talazoparib) capsules
What is the most important information I should know about TALZENNA? TALZENNA may cause serious side effects, including: • Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with TALZENNA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with TALZENNA. •TALZENNA may affect how your body makes bloods cells. This may lead to low red blood cell counts (anemia), low white blood cell counts, and low platelet counts. Symptoms of low blood cell counts are common during treatment with TALZENNA, but can be a sign of serious problems, including MDS or AML. Tell your healthcare provider if you havedevelop any of the following symptoms during treatment with TALZENNA:
○ weakness ○ weight loss ○ fever ○ frequent infections | ○ blood in urine or stool ○ shortness of breath ○ feeling very tired ○ bruising or bleeding more easily
Your healthcare provider will do blood tests to check your blood cell counts: ○ every month during treatment with TALZENNA. ○ weekly if you have low blood cell counts that last a long time. Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with TALZENNA if you get certain side effects. See “What are the possible side effects of TALZENNA?” below for other side effects of TALZENNA.
What is TALZENNA? TALZENNA is a prescription medicine used: •alone to treat adults with human epidermal growth factor receptor 2 (HER2)-negative breast cancer: owho have a certain type of an abnormal inherited BRCA gene, and owhose cancer has spread to other parts of the body (locally advanced or metastatic). Your healthcare provider will perform a test to make sure that TALZENNA is right for you. •in combination with a medicine called enzalutamide, to treat adults with prostate cancer owithwho have certain abnormal inherited or acquired genes called homologous recombination repair (HRR) genes), and owhichwhose nocancer has spread to other parts of the body (metastatic) and: ono longer responds to hormone therapy or surgical treatment to lower testosterone, andor hasohas spreadnot yet been treated with, or still responds to, otherhormone partstherapy ofor thesurgical bodytreatment (metastatic)to lower testosterone. Your healthcare provider will perform a test to make sure that TALZENNA is right for you. It is not known if TALZENNA is safe and effective in children.
Before taking TALZENNA, tell your healthcare provider about all of your medical conditions, including if you: •have kidney problems. •are pregnant or plan to become pregnant. TALZENNA can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with TALZENNA. Females who are able to become pregnant: oYour healthcare provider may do a pregnancy test before you start treatment with TALZENNA. oYou should useoUse effective birth control (contraception) during treatment with TALZENNA and for 7 months after the last dose of TALZENNA. Talk to your healthcare provider about forms of birth control that may be right for you. oTell your healthcare provider right away if you are pregnant or think you are pregnant during treatment with TALZENNA. Males with female partners who are pregnant or are able to become pregnant: oYou should useoUse effective birth control during treatment with TALZENNA and for 4 months after the last dose of TALZENNA. •are breastfeeding or plan to breastfeed. It is not known if TALZENNA passes into your breast milk. Do not breastfeed during treatment with TALZENNA and for 1 month after the last dose of TALZENNA. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking TALZENNA with certain other medicines can affect how TALZENNA works and may cause side effects. Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.
How should I take TALZENNA? •Take TALZENNA exactly as your healthcare provider tells you. • Do not change your dose or stop taking TALZENNA without first talking with your healthcare provider. •If you are prescribed TALZENNA for breast cancer, take TALZENNA 1 time a day. •If you are prescribed TALZENNA for prostate cancer: oTake TALZENNA with enzalutamide 1 time a day. oYou should start or continue a gonadotropin-releasing hormone (GnRH) analog therapy during your treatment with TALZENNA and enzalutamide unless you have had a surgery to lower the amount of testosterone in your body (surgical castration). •Take TALZENNA with or without food. •Swallow TALZENNA capsules whole. Do not dissolveopen or opendissolve TALZENNA capsules. •If you vomit or miss a dose of TALZENNA, take your next dose at your regular time. Do not take an extra dose to make up for a missed dose.
What are the possible side effects of TALZENNA? TALZENNA may cause serious side effects, including: • See “What is the most important information I should know about TALZENNA?” The most common side effects of TALZENNA when taken alone include:
•decreased red blood cell counts •decreased white blood cell counts •tirednessdecreased orplatelet weaknesscounts •decreasedtiredness plateletor countsweakness •increased blood sugar levels •increased liver function tests •nausea | •headache •decreased blood calcium levels | •nausea •headache •vomiting •hair loss •diarrhea •decreased appetite
The most common side effects of TALZENNA when taken in combination with enzalutamide include:
•decreased red blood cell counts •decreased white blood cell counts •tiredness or weakness •decreased platelet counts •decreased calcium in the blood •nausea •decreased appetite •decreased sodium in the blood | •decreased phosphate in the blood •bone injuries •decreased magnesium in the blood •dizziness •increased bilirubin in the blood •decreased potassium in the blood •changes in your sense of taste
•decreased red blood cell counts •decreased white blood cell counts •decreased platelet counts •tiredness or weakness •decreased protein (albumin) levels in the blood | •decreased blood calcium levels •back pain •decreased appetite •nausea
TALZENNA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of TALZENNA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store TALZENNA? •Store TALZENNA at 68°F to 77°F (20°C to 25°C). Keep TALZENNA and all medicines out of the reach of children.
General information about the safe and effective use of TALZENNA. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TALZENNA for a condition for which it is not prescribed. Do not give TALZENNA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare providerpharmacist or pharmacisthealthcare provider for information about TALZENNA that is written for health professionals.
What are the ingredients in TALZENNA? Active ingredient: talazoparib tosylate Inactive ingredients: silicified microcrystalline cellulose (sMCC). The capsule shells contain hypromellose (HPMC), yellow iron oxide, red iron oxide and titanium dioxide. The printing ink contains shellac, black iron oxide, potassium hydroxide, ammonium hydroxide, and propylene glycol. For more information, go to www.pfizer.com or call 1-800-438-1985. LAB-1272-67.0

Untitled section

Changed1 word added, 1 removed
This product's labeling may have been updated. For the most recent prescribing information, please visit http://www.pfizer.com.
LAB-1271-910.0

Unchanged: Dosage forms and strengths, Contraindications, Description, Nonclinical toxicology, Patient counseling information, PRINCIPAL DISPLAY PANEL - 0.25 mg Capsule Bottle Label, PRINCIPAL DISPLAY PANEL - 0.25 mg Capsule Bottle Carton, PRINCIPAL DISPLAY PANEL - 1 mg Capsule Bottle Label, PRINCIPAL DISPLAY PANEL - 1 mg Capsule Bottle Carton, PRINCIPAL DISPLAY PANEL - 0.5 mg Capsule Bottle Label, PRINCIPAL DISPLAY PANEL - 0.5 mg Capsule Bottle Carton, PRINCIPAL DISPLAY PANEL - 0.75 mg Capsule Bottle Label, PRINCIPAL DISPLAY PANEL - 0.75 mg Capsule Bottle Carton, PRINCIPAL DISPLAY PANEL - 0.1 mg Capsule Bottle Label, PRINCIPAL DISPLAY PANEL - 0.1 mg Capsule Bottle Carton, PRINCIPAL DISPLAY PANEL - 0.35 mg Capsule Bottle Label, PRINCIPAL DISPLAY PANEL - 0.35 mg Capsule Bottle Carton.

Every version

20 versions of set f2423edd-6d24-495c-aec1-c2f457f08d9a, newest first.

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.